Fibromyalgia: new international criteria for diagnosis and treatment strategies


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

The article discusses the challenging issue of differential diagnosis of diseases manifested as fibromyalgia syndrome. The authors describe the "old" and new criteria for the clinical diagnosis of fibromyalgia. It is emphasized that a proficient clinical evaluation to clarify the causes of pain syndrome is of greater importance than additional diagnostic testing. The diagnosis of fibromyalgia can be made in primary care settings using the criteria of the American College of Rheumatology (ACR, 2010), given normal results of physical examination and routine laboratory testing excluding other diseases. The main groups of diseases to consider in the differential diagnosis of fibromyalgia include the following: musculoskeletal and connective tissue diseases, endocrine, gastrointestinal, infectious diseases, cancer, neurological and mental health disorders, iatrogenic pain. Particular attention should be paid to ankylosing spondylitis and myofascial pain syndrome. Problems in treating fibromyalgia are discussed. The authors review the properties of flupirtine (Nolodatak) that help resolve complex diagnostic challenges when it is impossible to rapidly diagnose a disease manifested by pain syndrome.

Texto integral

Acesso é fechado

Sobre autores

Oleg Kolokolov

Saratov State Medical University named after V. I. Razumovsky

Email: kolokolov@inbox.ru
Dr.Med.Sci., Head of the Department of Neurology of the K.N. Tret'yakov IAPE

Angelica Kolokova

Saratov State Medical University named after V. I. Razumovsky

Email: kolokolov@inbox.ru
Ph.D., Teaching Assistant at the Department of Neurology of the K.N. Tret'yakov IAPE

Inna Sitkali

Saratov State Medical University named after V. I. Razumovsky

Email: kolokolov@inbox.ru
Ph.D. Student at the Department of Neurology of the K.N. Tret'yakov IAPE

Bibliografia

  1. Ablin J.N., Amital H., Ehrenfeld M. et al. Guidelines for the diagnosis and treatment of the fibromyalgia syndrome [in Hebrew] // Harefuah. 2013; 152: 742-747,751,750.
  2. Eich W., Hauser W., Arnold B. et al. Fibromyalgia syndrome. Definition, classification, clinical diagnosis and prognosis [in German] // Schmerz. 2012; 26: 247-258.
  3. Fitzcharles M.A., Ste-Marie P.A., Goldenberg D.L. et al. Canadian Pain Society and Canadian Rheumatology Association recommendations for rational care of persons with fibromyalgia. A summary report // J Rheumatol. 2013; 40: 1388-1393.
  4. Macfarlane G.J., Kronisch C., Dean L.E. et al. EULAR revised recommendations for the management of fibromyalgia // Ann Rheum Dis. 2017; 76: 318-328.
  5. Wolfe F., Walitt B. Fibromyalgia is over-diagnosed in the general population // Arthritis Rheumatol. 2016; 68: 3043-3044.
  6. Marques A.P., Santo A.S., Berssaneti A.A. et al. Prevalence of fibromyalgia: literature review update // Rev Bras Reumatol. 2016; pii: S0482-5004(16)30174-7.
  7. Стороженко О.Н., Лесник О.М., Макбет Д., Макфарлайи Г. Хроническая генерализованная боль в теле: частота в популяции и связь с ментальными расстройствами личности. Научно-практическая ревматология. 2002 ; 2:54. [Storozhenko O.N., Lesnik O.M., Makbet D., Makfarlayi G. Chronic generalized body pain: frequency in the population and the relationship with mental disorders personality. Scientific-practical rheumatology. 2002;2:54 (in Russ.)]
  8. Hauser W., Perrot S., Sommer C. et al. Diagnostic confounders of chronic widespread pain: not always fibromyalgia // PAIN Reports. 2017; 2(3): e598.
  9. Wolfe F., Smythe H.A., Yunus M.B. et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee // Arthritis Rheum. 1990; 33(2): 160-172.
  10. Данилов А.Б. Диагностика и лечение фибромиалгии. Лечащий врач. 2012;5:30-4. [Danilov A.B. Diagnosis and treatment of fibromyalgia. Doctor. 2012;5:30-4 (in Russ.)]
  11. Wolfe F., Clauw D.J., Fitzcharles M.A. et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity // Arthritis Care Res (Hoboken). 2010; 62(5): 600-610.
  12. Wolfe F., Clauw D.J., Fitzcharles M.A. et al. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia // J Rheumatol. 2011; 38(6): 11 13-1122.
  13. Wolfe F. Editorial: the status of fibromyalgia criteria // Arthritis Rheumatol. 2015; 67(2): 330-333.
  14. Wolfe F., Fitzcharles M.A., Goldenberg D.L. et al. Comparison of Physician-Based and Patient-Based Criteria for the Diagnosis of Fibromyalgia // Arthritis Care Res (Hoboken). 2016; 68(5): 652-659.
  15. Fitzcharles M.A., Boulos P. Inaccuracy in the diagnosis of fibromyalgia syndrome: analysis of referrals // Rheumatology (Oxford). 2003; 42: 263-267.
  16. Fitzcharles M.A., Esdaile J.M. The overdiagnosis of fibromyalgia syndrome // Am J Med. 1997; 103: 44-50.
  17. Perrot S., Dieude P., Perocheau D., Allanore Y. Comparison of pain, pain burden, coping strategies, and attitudes between patients with systemic sclerosis and patients with rheumatoid arthritis: a cross-sectional study // Pain Med. 2013; 14: 1776-1785.
  18. Ablin J.N., Eshed I., Berman M. et al. Prevalence of axial spondyloarthropathy among patients suffering from fibromyalgia - an MRI study with application of the ASAS classification criteria // Arthritis Care Res (Hoboken). 2016. doi: 10.1002/acr.22967.
  19. Baraliakos X., Maksymowych W.P. Imaging in the diagnosis and management of axial spondyloarthritis // Best Pract Res Clin Rheumatol. 2016; 30: 608-623.
  20. Roussou E., Ciurtin C. Clinical overlap between fibromyalgia tender points and enthesitis sites in patients with spondyloarthritis who present with inflammatory back pain // Clin Exp Rheumatol. 2012; 30(6 suppl 74): 24-30.
  21. Sepriano A., Landewe R., van der Heijde D. et al. Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: a final analysis // Ann Rheum Dis. 2016; 75: 1034-1042.
  22. Tough E.A., White A.R., Richards S., Campbell J. Variability of criteria used to diagnose myofascial trigger point pain syndrome - evidence from a review of the literature // Clin J Pain. 2007; 23: 278-286.
  23. Clauw D.J. Fibromyalgia: a clinical review // JAMA. 2014; 31 1: 1547-1555.
  24. Fernandez de Las Penas C., Arendt-Nielsen L. Myofascial pain and fibromyalgia: two different but overlapping disorders // Pain Manag. 2016; 6: 401-408.
  25. Ge H.Y., Wang Y., Danneskiold-Samsoe B. et al. The predetermined sites of examination for tender points in fibromyalgia syndrome are frequently associated with myofascial trigger points // J Pain. 2010; 11: 644-651.
  26. Schneider M.J. Tender points/fibromyalgia vs. trigger points/myofascial pain syndrome: a need for clarity in terminology and differential diagnosis // J Manipulative Physiol Ther. 1995; 18: 398-406.
  27. Ahmad J., Tagoe C.E. Fibromyalgia and chronic widespread pain in autoimmune thyroid disease // Clin Rheumatol. 2014; 33: 885-891.
  28. Wintermeyer E., Ihle C., Ehnert S. et al. Crucial role of vitamin D in the musculoskeletal system // Nutrients. 2016; 8: 319.
  29. Yong W.C., Sanguankeo A., Upala S. Effect of vitamin D supplementation in chronic widespread pain: a systematic review and meta-analysis // Clin Rheumatol. 2017. doi: 10.1007/s10067-017-3754-y.
  30. Aziz I., Dwivedi K., Sanders D.S. From coeliac disease to noncoeliac gluten sensitivity; should everyone be gluten free? // Curr Opin Gastroenterol. 2016; 32: 120-127.
  31. Hsu V.M., Patella S.J., Sigal L.H. «Chronic Lyme disease» as the incorrect diagnosis in patients with fibromyalgia // Arthritis Rheum. 1993; 36: 1493-1500.
  32. Kozanoglu E., Canataroglu A., Abayli B. et al. Fibromyalgia syndrome in patients with hepatitis C infection // Rheumatol Int. 2003; 23: 248-251.
  33. Wormser G.P., Weitzner E., McKenna D. et al. Long-term assessment of fibromyalgia in patients with culture-confirmed Lyme disease // Arthritis Rheumatol. 2014; 67: 837-839.
  34. Burgstaller J.M., Schuffler P.J., Buhmann J.M. et al. Is there an association between pain and magnetic resonance imaging parameters in patients with lumbar spinal stenosis? // Spine (Phila Pa 1976). 2016; 41: E1053-1062.
  35. Mader R., Novofastovski I., Rosner E. et al. Nonarticular tenderness and functional status in patients with diffuse idiopathic skeletal hyperostosis // J Rheumatol. 2010; 37: 1911-1916.
  36. Mader R., Verlaan J.J., Buskila D. Diffuse idiopathic skeletal hyperostosis: clinical features and pathogenic mechanisms // Nat Rev Rheumatol. 2013; 9: 741-750.
  37. Gesquiere-Dando A., Attarian S., Maues De Paula A. et al. Fibromyalgia-like symptoms associated with irritable bowel syndrome: a challenging diagnosis of late-onset Pompe disease // Muscle Nerve. 2015; 52: 300-304.
  38. Lucia A., Nogales-Gadea G., Perez M. et al. McArdle disease: what do neurologists need to know? // Nat Clin Pract Neurol. 2008; 4: 568-577.
  39. Bays H. Statin safety: an overview and assessment of the data - 2005 // Am J Cardiol. 2006; 97: 6C-26C.
  40. Mosshammer D., Schaeffeler E., Schwab M., Morike K. Mechanisms and assessment of statin-related muscular adverse effects // Br J Clin Pharmacol. 2014; 78: 454-466.
  41. Rabar S., Harker M., O'Flynn N., Wierzbicki A.S. Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance // BMJ. 2014; 349: g4356.
  42. Harris R.E., Clauw D.J., Scott D.J. et al. Decreased central mu-opioid receptor availability in fibromyalgia // J Neurosci. 2007; 27: 10000-6.
  43. Hayhurst C.J., Durieux M.E. Differential opioid tolerance and opioid-induced hyperalgesia: a clinical reality // Anesthesiology. 2016; 124: 483-488.
  44. Borrie A.E., Kim R.B. Molecular basis of aromatase inhibitor associated arthralgia: known and potential candidate genes and associated biomarkers // Expert Opin Drug Metab Toxicol. 2017; 13: 149-156.
  45. Laroche F., Coste J., Medkour T. et al. Classification of and risk factors for estrogen deprivation pain syndromes related to aromatase inhibitor treatments in women with breast cancer: a prospective multicenter cohort study // J Pain. 2014; 15: 293-303.
  46. Clark D.W., Strandell J. Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors? // Eur J Clin Pharmacol. 2006; 62: 473-479.
  47. Bello N., Etcheto A., Beal C. et al. Evaluation of the impact of fibromyalgia in disease activity and treatment effect in spondyloarthritis // Arthritis Res Ther. 2016; 18: 42.
  48. Wolfe F., Clauw D.J., Fitzcharles M.A. et al. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia // J Rheumatol. 2011; 38: 1113-1122.
  49. Defazio G., Berardelli A., Fabbrini G. et al. Pain as a nonmotor symptom of Parkinson disease: evidence from a casecontrol study // Arch Neurol. 2008; 65: 1191-1194.
  50. Negre-Pages L., Regragui W., Bouhassira D. et al. Chronic pain in Parkinson's disease: the cross-sectional French DoPaMiP survey // Mov Disord. 2008; 23: 1361-1369.
  51. Toda K., Harada T. Prevalence, classification, and etiology of pain in Parkinson's disease: association between Parkinson's disease and fibromyalgia or chronicwidespread pain // Tohoku J ExpMed. 2010; 222: 1 -5.
  52. Yilmaz U., Bird T.T., Carter G.T. et al. Pain in hereditary neuropathy with liability to pressure palsy: an association with fibromyalgia syndrome? // Muscle Nerve. 2015; 51: 385-390.
  53. Caro X.J., Winter E.F. The role and importance of small fiber neuropathy in fibromyalgia pain // Curr Pain Headache Rep. 2015; 19: 55.
  54. Uceyler N., Sommer C. Objective evidence that small-fiber polyneuropathy underlies some illnesses currently labeled as fibromyalgia // PAIN. 2013; 154: 2569.
  55. Uceyler N., Zeller D., Kahn A.K. et al. Small fibre pathology in patients with fibromyalgia syndrome // Brain. 2013; 136(pt 6): 1857-1867.
  56. Perovic S., Pialoglou P., Schroder H.C. et al. Flupirtine increases the levels of glutathione and Bc1-2 in hNT (human Ntera/D1) neurons: mode of action of the drug-mediated anti-apoptotic effect // Eur J Pharmacol. 1996; 12: 157-164.
  57. Jakob R., Krieglsteinet J. Influence of flupirtine on a G-protein coupled inwardly rectifying potassium current in hippocampal neurons // Br J Pharmacol. 1997; 122: 1333-1338.
  58. Sampath D., Valdez R., White A.M., Raol Y.H. Anticonvulsant effect of flupirtine in an animal model of neonatal hypoxic-ischemic encephalopathy // Neuropharmacology. 2017; 123: 126-135.
  59. Worz R. Flupirtine in chronic myofascial pain conditions // Fortschr Med. 1991; 109 (6): 158-160.
  60. Stoll A.L. Fibromyalgia symptoms relieved by flupirtine: an open-label case series // Psychosomatics. 2000; 41(4): 371-372.
  61. Uberall M.A., Mueller-Schwefe G.H., Terhaag B.Efficacy and safety of flupirtine modified release for the management of moderate to severe chronic low back pain: results of SUPREME, a prospective randomized, double-blind, placebo- and active-controlled parallel-group phase IV study // Curr Med Res Opin. 2012; 28(10): 1617-1634.
  62. Ueberall M.A., Mueller-Schwefe G.H., Terhaag B. Efficacy and tolerability of flupirtine in subacute/ chronic musculoskeletal pain - results of a patient level, pooled re-analysis of randomized, double-blind, controlled trials // Int J Clin Pharmacol Ther. 2011; 49(1 1): 637-647.
  63. Devulder J. Flupirtine in pain management: pharmacological properties and clinical use // CNS Drugs. 2010; 24(10): 867-881.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2017

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies